1. Mbalaviele G, Novack DV, Schett G, Teitelbaum SL. Inflammatory osteolysis: a conspiracy against bone. The Journal of clinical investigation. 2017;127(6):2030-9.
2. Walsh MC, Takegahara N, Kim H, Choi Y. Updating osteoimmunology: regulation of bone cells by innate and adaptive immunity. Nature reviews Rheumatology. 2018;14(3):146-56.
3. Black DM, Rosen CJ. Clinical Practice. Postmenopausal Osteoporosis. The New England journal of medicine. 2016;374(3):254-62.
4. Takeuchi T, Tanaka Y, Soen S, Yamanaka H, Yoneda T, Tanaka S, et al. Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study): a randomised, double-blind, placebo-controlled phase 3 trial. Ann Rheum Dis. 2019;78(7):899-907.
5. Tsourdi E, Zillikens MC, Meier C, Body JJ, Gonzalez Rodriguez E, Anastasilakis AD, et al. Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS. The Journal of clinical endocrinology and metabolism. 2020.
6. Tsukasaki M, Takayanagi H. Osteoimmunology: evolving concepts in bone-immune interactions in health and disease. Nature reviews Immunology. 2019;19(10):626-42.
7. Bae S, Lee MJ, Mun SH, Giannopoulou EG, Yong-Gonzalez V, Cross JR, et al. MYCdependent oxidative metabolism regulates osteoclastogenesis via nuclear receptor ERRalpha. The Journal of clinical investigation. 2017;127(7):2555-68.
8. Nishikawa K, Iwamoto Y, Kobayashi Y, Katsuoka F, Kawaguchi S, Tsujita T, et al. DNA methyltransferase 3a regulates osteoclast differentiation by coupling to an Sadenosylmethionine-producing metabolic pathway. Nature medicine. 2015;21(3):281-7.
9. Lemma S, Sboarina M, Porporato PE, Zini N, Sonveaux P, Di Pompo G, et al. Energy metabolism in osteoclast formation and activity. The international journal of biochemistry & cell biology. 2016;79:168-80.
10. Jin Z, Wei W, Yang M, Du Y, Wan Y. Mitochondrial complex I activity suppresses inflammation and enhances bone resorption by shifting macrophage-osteoclast polarization. Cell metabolism. 2014;20(3):483-98.
11. Indo Y, Takeshita S, Ishii KA, Hoshii T, Aburatani H, Hirao A, et al. Metabolic regulation of osteoclast differentiation and function. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2013;28(11):2392-9.
12. Park-Min KH. Metabolic reprogramming in osteoclasts. Seminars in immunopathology. 2019;41(5):565-72.
13. Ivashkiv LB. Metabolic-epigenetic coupling in osteoclast differentiation. Nature medicine. 2015;21(3):212-3.
14. Murata K, Fang C, Terao C, Giannopoulou EG, Lee YJ, Lee MJ, et al. HypoxiaSensitive COMMD1 Integrates Signaling and Cellular Metabolism in Human Macrophages and Suppresses Osteoclastogenesis. Immunity. 2017;47(1):66-79 e5.
15. Palazon A, Goldrath AW, Nizet V, Johnson RS. HIF transcription factors, inflammation, and immunity. Immunity. 2014;41(4):518-28.
16. Gu F, Lin Y, Wang Z, Wu X, Ye Z, Wang Y, et al. Biological roles of LSD1 beyond its demethylase activity. Cellular and molecular life sciences : CMLS. 2020;77(17):3341-50.
17. Kitaura H, Zhou P, Kim HJ, Novack DV, Ross FP, Teitelbaum SL. M-CSF mediates TNF-induced inflammatory osteolysis. The Journal of clinical investigation. 2005;115(12):3418- 27.
18. Sorensen MG, Henriksen K, Schaller S, Henriksen DB, Nielsen FC, Dziegiel MH, et al. Characterization of osteoclasts derived from CD14+ monocytes isolated from peripheral blood. Journal of bone and mineral metabolism. 2007;25(1):36-45.
19. Lee JY, Park JH, Choi HJ, Won HY, Joo HS, Shin DH, et al. LSD1 demethylates HIF1alpha to inhibit hydroxylation and ubiquitin-mediated degradation in tumor angiogenesis. Oncogene. 2017;36(39):5512-21.
20. Sacca CD, Gorini F, Ambrosio S, Amente S, Faicchia D, Matarese G, et al. Inhibition of lysine-specific demethylase LSD1 induces senescence in Glioblastoma cells through a HIF1alpha-dependent pathway. Biochimica et biophysica acta Gene regulatory mechanisms. 2019;1862(5):535-46.
21. Ishigaki K, Kochi Y, Suzuki A, Tsuchida Y, Tsuchiya H, Sumitomo S, et al. Polygenic burdens on cell-specific pathways underlie the risk of rheumatoid arthritis. Nature genetics. 2017;49(7):1120-5.
22. Takeuchi Y, Hirota K, Sakaguchi S. Impaired T cell receptor signaling and development of T cell-mediated autoimmune arthritis. Immunological reviews. 2020;294(1):164-76.
23. Dery MA, Michaud MD, Richard DE. Hypoxia-inducible factor 1: regulation by hypoxic and non-hypoxic activators. The international journal of biochemistry & cell biology. 2005;37(3):535-40.
24. McInturff AM, Cody MJ, Elliott EA, Glenn JW, Rowley JW, Rondina MT, et al. Mammalian target of rapamycin regulates neutrophil extracellular trap formation via induction of hypoxia-inducible factor 1 alpha. Blood. 2012;120(15):3118-25.
25. Finlay DK, Rosenzweig E, Sinclair LV, Feijoo-Carnero C, Hukelmann JL, Rolf J, et al. PDK1 regulation of mTOR and hypoxia-inducible factor 1 integrate metabolism and migration of CD8+ T cells. The Journal of experimental medicine. 2012;209(13):2441-53.
26. Rius J, Guma M, Schachtrup C, Akassoglou K, Zinkernagel AS, Nizet V, et al. NFkappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha. Nature. 2008;453(7196):807-11.
27. Hayashi Y, Yokota A, Harada H, Huang G. Hypoxia/pseudohypoxia-mediated activation of hypoxia-inducible factor-1alpha in cancer. Cancer science. 2019;110(5):1510-7.
28. Kuschel A, Simon P, Tug S. Functional regulation of HIF-1alpha under normoxia--is there more than post-translational regulation? Journal of cellular physiology. 2012;227(2):514- 24.
29. Cimmino F, Avitabile M, Lasorsa VA, Montella A, Pezone L, Cantalupo S, et al. HIF-1 transcription activity: HIF1A driven response in normoxia and in hypoxia. BMC medical genetics. 2019;20(1):37.
30. Tsukasaki M, Huynh NC, Okamoto K, Muro R, Terashima A, Kurikawa Y, et al. Stepwise cell fate decision pathways during osteoclastogenesis at single-cell resolution. Nature metabolism. 2020;2(12):1382-90.
31. Kim Y, Nam HJ, Lee J, Park DY, Kim C, Yu YS, et al. Methylation-dependent regulation of HIF-1alpha stability restricts retinal and tumour angiogenesis. Nature communications. 2016;7:10347.
32. Zheng YC, Ma J, Wang Z, Li J, Jiang B, Zhou W, et al. A Systematic Review of Histone Lysine-Specific Demethylase 1 and Its Inhibitors. Medicinal research reviews. 2015;35(5):1032- 71.
33. Fang Y, Liao G, Yu B. LSD1/KDM1A inhibitors in clinical trials: advances and prospects. Journal of hematology & oncology. 2019;12(1):129.
34. Fiskus W, Sharma S, Shah B, Portier BP, Devaraj SG, Liu K, et al. Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells. Leukemia. 2014;28(11):2155-64.
35. Munehira Y, Yang Z, Gozani O. Systematic Analysis of Known and Candidate Lysine Demethylases in the Regulation of Myoblast Differentiation. Journal of molecular biology. 2017;429(13):2055-65.
36. Sun J, Ermann J, Niu N, Yan G, Yang Y, Shi Y, et al. Histone demethylase LSD1 regulates bone mass by controlling WNT7B and BMP2 signaling in osteoblasts. Bone research. 2018;6:14.
37. Falconer J, Murphy AN, Young SP, Clark AR, Tiziani S, Guma M, et al. Review: Synovial Cell Metabolism and Chronic Inflammation in Rheumatoid Arthritis. Arthritis & rheumatology (Hoboken, NJ). 2018;70(7):984-99.
38. Liu W, Fan JB, Xu DW, Zhu XH, Yi H, Cui SY, et al. Knockdown of LSD1 ameliorates the severity of rheumatoid arthritis and decreases the function of CD4 T cells in mouse models. International journal of clinical and experimental pathology. 2018;11(1):333-41.
39. Sorna V, Theisen ER, Stephens B, Warner SL, Bearss DJ, Vankayalapati H, et al. High-throughput virtual screening identifies novel N'-(1-phenylethylidene)-benzohydrazides as potent, specific, and reversible LSD1 inhibitors. Journal of medicinal chemistry. 2013;56(23):9496-508.
40. Pishas KI, Drenberg CD, Taslim C, Theisen ER, Johnson KM, Saund RS, et al. Therapeutic Targeting of KDM1A/LSD1 in Ewing Sarcoma with SP-2509 Engages the Endoplasmic Reticulum Stress Response. Molecular cancer therapeutics. 2018;17(9):1902-16.